Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Abstract

Background: Recently, peroxiredoxin3 (PRDX3) was identified as a novel molecular marker for the progression of hepatocellular carcinoma (HCC). However, its potential clinical application as a serum marker for the early diagnosis and prognosis of HCC has not been investigated. Methods: PRDX3, alpha-fetaprotein (AFP), and other biochemical parameters were measured in serum samples from 297 Chinese patients, including 96 with HCC, 98 with liver cirrhosis (LC), and 103 healthy controls (HCs). Correlations between serum PRDX3 expression and clinicopathological variables and the relationship between serum PRDX3 expression and prognosis were analyzed. Results: Serum PRDX3 was significantly higher in HCC patients than in the LC and HC groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 85.9% and 75.3%, respectively, at a cutoff of 153.26 ng/mL, and the area under the curve was 0.865. Moreover, serum PRDX3 expression was strongly associated with AFP level, tumor diameter, TNM stage, and portal vein invasion. Kaplan-Meier curve analysis revealed that HCC patients with high serum PRDX3 expression had a shorter median survival time than those with low PRDX3 expression. Moreover, serum PRDX3 expression was an independent risk factor for overall survival. The inverse correlation between serum PRDX3 and patient survival remained significant in patients with early-stage HCC and in those with normal serum AFP levels. Conclusions: Serum PRDX3 can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC.

Elevated PIVKA-II is Associated with Early Recurrence and Poor Prognosis in BCLC 0-A Hepatocellular Carcinomas

“…α-Fetoprotein (AFP) was first introduced as a serological marker for HCC and has since been used in clinical practice both for diagnosis and as an indicator of tumor response to treatment (Gupta et al, 2013;Shi et al, 2014;Wang et al, 2014). Previous studies have demonstrated that PIVKA-II (prothrombin induced by the absence of vitamin K or antagonist-II) is also an effective marker for HCC, and that an elevated PIVKA-II level appears to predict worse tumor behavior.…”

The prognostic values of the peroxiredoxins family in ovarian cancer

“…In addition, Hintsala et al [58] showed that up-regulation of PRDX3 in melanocytic skin tumors was correlated with shortened melanoma-specific survival. Furthermore, PRDX3 overexpression was strongly associated with the progression of hepatocellular carcinoma; patients with high serum PRDX3 levels had a shorter median survival time when compared to those with low serum PRDX3 level [59]. Li and co-workers have previously reported that the expression of PRDX3 was up-regulated in ovarian serous cystadenocarinoma specimens when compared with the normal ovarian epithelia [56].…”

Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation

“…Viral replication in viral hepatitis and multiple tumors increases the risk for the late recurrence (30,31). However, the molecular pathogenesis underlying tumor recurrence remains largely unknown, which seriously hinders the improvement of the clinical management of HCC (32,33). In previous years, it was widely accepted that abnormal gene expression constituted one of the major characteristics of tumor invasion and metastasis.…”